Comprehensive Stock Comparison
Compare Armata Pharmaceuticals, Inc. (ARMP) vs Eli Lilly and Company (LLY) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth |  LLY | 32.0% revenue growth vs ARMP's 14.2% |
| Quality / Margins | LLY | 31.0% net margin vs ARMP's -9.3% |
| Stability / Safety |  ARMP | Beta 0.21 vs LLY's 0.65 |
| Dividends | LLY | 0.5% yield; 10-year raise streak; ARMP pays no meaningful dividend |
| Momentum (1Y) | ARMP | +474.8% vs LLY's +8.6% |
| Efficiency (ROA) | LLY | 16.0% ROA vs ARMP's -52.4%, ROIC 33.7% vs -44.2% |
Who Each Stock Is For
Income & stability
ARMPDividend streak 0 yrs, beta 0.21
Growth exposure
LLYRev growth 32.0%, EPS growth 101.9%, 3Y rev CAGR 16.7%
Long-term compounding (10Y)
LLY13.2% 10Y total return vs ARMP's -98.0%
Sleep-well-at-night portfolio
ARMPLower volatility, beta 0.21, current ratio 0.23x
Defensive / Recession hedge
ARMPBeta 0.21, current ratio 0.23x
Business Model
What each company does and how it makes money
Armata Pharmaceuticals is a clinical-stage biotech company developing targeted bacteriophage therapies to treat antibiotic-resistant bacterial infections. It generates revenue primarily through research collaborations and partnerships — like its Merck deal — while advancing its pipeline of phage-based candidates through clinical trials. The company's key advantage is its proprietary bacteriophage platform technology, which offers a novel approach to targeting specific drug-resistant pathogens.
Eli Lilly is a global pharmaceutical company that discovers, develops, and markets innovative medicines for serious diseases like diabetes, cancer, and autoimmune disorders. It generates revenue primarily from drug sales — with diabetes treatments like Trulicity and Mounjaro contributing over 50% of revenue — and from oncology and immunology products. The company's competitive advantage lies in its deep research and development capabilities, particularly in diabetes and obesity treatments where it has established a strong patent-protected portfolio.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
LLY 3ARMP 1LLY6/6 metricsLLY5/7 metricsARMP4/6 metricsLLY1/1 metricsLLY leads in 3 of 6 categories (Financial Metrics, Profitability & Efficiency). ARMP leads in 1 (Total Returns). 2 tied.
Financial Metrics (TTM)
LLY is the larger business by revenue, generating $59.4B annually — 11757.0x ARMP's $5M. LLY is the more profitable business, keeping 31.0% of every revenue dollar as net income compared to ARMP's -9.3%. On growth, LLY holds the edge at +53.9% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ARMPArmata Pharmaceut… | LLYEli Lilly and Com… |
|---|---|---|
| RevenueTrailing 12 months | $5M | $59.4B |
| EBITDAEarnings before interest/tax | -$32M | $28.6B |
| Net IncomeAfter-tax profit | -$47M | $18.4B |
| Free Cash FlowCash after capex | -$27M | $9.0B |
| Gross MarginGross profit ÷ Revenue | +70.5% | +83.0% |
| Operating MarginEBIT ÷ Revenue | -6.6% | +45.0% |
| Net MarginNet income ÷ Revenue | -9.3% | +31.0% |
| FCF MarginFCF ÷ Revenue | -5.4% | +15.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | -61.0% | +53.9% |
| EPS Growth (YoY)Latest quarter vs prior year | -3.9% | +4.8% |
Valuation Metrics
| Metric | ARMPArmata Pharmaceut… | LLYEli Lilly and Com… |
|---|---|---|
| Market CapShares × price | $420M | $898.2B |
| Enterprise ValueMkt cap + debt − cash | $537M | $928.6B |
| Trailing P/EPrice ÷ TTM EPS | -22.19x | 85.70x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 29.43x |
| PEG RatioP/E ÷ EPS growth rate | — | 13.94x |
| EV / EBITDAEnterprise value multiple | — | 48.19x |
| Price / SalesMarket cap ÷ Revenue | 81.14x | 19.94x |
| Price / BookPrice ÷ Book value/share | — | 63.57x |
| Price / FCFMarket cap ÷ FCF | — | 2168.03x |
Profitability & Efficiency
On the Piotroski fundamental quality scale (0–9), LLY scores 6/9 vs ARMP's 2/9, reflecting solid financial health.
| Metric | ARMPArmata Pharmaceut… | LLYEli Lilly and Com… |
|---|---|---|
| ROE (TTM)Return on equity | — | +77.2% |
| ROA (TTM)Return on assets | -52.4% | +16.0% |
| ROICReturn on invested capital | -44.2% | +33.7% |
| ROCEReturn on capital employed | -70.7% | +40.2% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 6 |
| Debt / EquityFinancial leverage | — | 2.36x |
| Net DebtTotal debt minus cash | $117M | $30.4B |
| Cash & Equiv.Liquid assets | $9M | $3.3B |
| Total DebtShort + long-term debt | $127M | $33.6B |
| Interest CoverageEBIT ÷ Interest expense | -2.12x | 26.09x |
Total Returns (with DRIP)
A $10,000 investment in LLY five years ago would be worth $49,693 today (with dividends reinvested), compared to $25,857 for ARMP. Over the past 12 months, ARMP leads with a +474.8% total return vs LLY's +8.6%. The 3-year compound annual growth rate (CAGR) favors ARMP at 56.0% vs LLY's 47.3% — a key indicator of consistent wealth creation.
| Metric | ARMPArmata Pharmaceut… | LLYEli Lilly and Com… |
|---|---|---|
| YTD ReturnYear-to-date | +77.0% | -6.9% |
| 1-Year ReturnPast 12 months | +474.8% | +8.6% |
| 3-Year ReturnCumulative with dividends | +279.4% | +219.8% |
| 5-Year ReturnCumulative with dividends | +158.6% | +396.9% |
| 10-Year ReturnCumulative with dividends | -98.0% | +1316.4% |
| CAGR (3Y)Annualised 3-year return | +56.0% | +47.3% |
Risk & Volatility
ARMP is the less volatile stock with a 0.21 beta — it tends to amplify market swings less than LLY's 0.65 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. LLY currently trades 88.5% from its 52-week high vs ARMP's 71.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ARMPArmata Pharmaceut… | LLYEli Lilly and Com… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.21x | 0.65x |
| 52-Week HighHighest price in past year | $16.34 | $1133.95 |
| 52-Week LowLowest price in past year | $0.90 | $623.78 |
| % of 52W HighCurrent price vs 52-week peak | +71.1% | +88.5% |
| RSI (14)Momentum oscillator 0–100 | 71.9 | 44.8 |
| Avg Volume (50D)Average daily shares traded | 50K | 3.0M |
Analyst Outlook
Wall Street rates ARMP as "Buy" and LLY as "Buy". Consensus price targets imply 21.0% upside for LLY (target: $1214) vs -22.5% for ARMP (target: $9). LLY is the only dividend payer here at 0.52% yield — a key consideration for income-focused portfolios.
| Metric | ARMPArmata Pharmaceut… | LLYEli Lilly and Com… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $9.00 | $1214.28 |
| # AnalystsCovering analysts | 4 | 44 |
| Dividend YieldAnnual dividend ÷ price | — | +0.5% |
| Dividend StreakConsecutive years of raises | 0 | 10 |
| Dividend / ShareAnnual DPS | — | $5.18 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +0.3% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Mar 20 | Mar 26 | Change |
|---|---|---|---|
| Armata Pharmaceutic… (ARMP) | 100 | 303.72 | +203.7% |
| Eli Lilly and Compa… (LLY) | 100 | 726.34 | +626.3% |
Eli Lilly and Compa… (LLY) returned +397% over 5 years vs Armata Pharmaceutic… (ARMP)'s +159%. A $10,000 investment in LLY 5 years ago would be worth $49,693 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| Armata Pharmaceutic… (ARMP) | $475000.00 | $5M | +989.3% |
| Eli Lilly and Compa… (LLY) | $20.0B | $45.0B | +125.7% |
Armata Pharmaceuticals, Inc.'s revenue grew from $0M (2015) to $5M (2024) — a 30.4% CAGR. Eli Lilly and Company's revenue grew from $20.0B (2015) to $45.0B (2024) — a 9.5% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| Armata Pharmaceutic… (ARMP) | -108.6% | -3.7% | +96.6% |
| Eli Lilly and Compa… (LLY) | 12.1% | 23.5% | +94.8% |
Armata Pharmaceuticals, Inc.'s net margin went from -109% (2015) to -4% (2024). Eli Lilly and Company's net margin went from 12% (2015) to 24% (2024).
Chart 4P/E Ratio History — 7 Years
| Stock | 2018 | 2024 | Change |
|---|---|---|---|
| Eli Lilly and Compa… (LLY) | 37 | 65.9 | +78.1% |
Eli Lilly and Company has traded in a 15x–101x P/E range over 7 years; current trailing P/E is ~86x.
Chart 5EPS Growth — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| Armata Pharmaceutic… (ARMP) | -278.6 | -0.52 | +99.8% |
| Eli Lilly and Compa… (LLY) | 2.18 | 11.71 | +437.2% |
Armata Pharmaceuticals, Inc.'s EPS grew from $-278.60 (2015) to $-0.52 (2024). Eli Lilly and Company's EPS grew from $2.18 (2015) to $11.71 (2024) — a 21% CAGR.
Chart 6Free Cash Flow — 5 Years
Armata Pharmaceuticals, Inc. generated $-39M FCF in 2024 (-58% vs 2021). Eli Lilly and Company generated $414M FCF in 2024 (-92% vs 2021).
ARMP vs LLY: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is ARMP or LLY a better buy right now?
Eli Lilly and Company (LLY) offers the better valuation at 85.7x trailing P/E (29.4x forward), making it the more compelling value choice. Analysts rate Armata Pharmaceuticals, Inc. (ARMP) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — ARMP or LLY?
Over the past 5 years, Eli Lilly and Company (LLY) delivered a total return of +396.9%, compared to +158.6% for Armata Pharmaceuticals, Inc. (ARMP). A $10,000 investment in LLY five years ago would be worth approximately $50K today (assuming dividends reinvested). Over 10 years, the gap is even starker: LLY returned +1316% versus ARMP's -98.0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — ARMP or LLY?
By beta (market sensitivity over 5 years), Armata Pharmaceuticals, Inc. (ARMP) is the lower-risk stock at 0.21β versus Eli Lilly and Company's 0.65β — meaning LLY is approximately 207% more volatile than ARMP relative to the S&P 500.
04Which has better profit margins — ARMP or LLY?
Eli Lilly and Company (LLY) is the more profitable company, earning 23.5% net margin versus -365.6% for Armata Pharmaceuticals, Inc. — meaning it keeps 23.5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LLY leads at 38.9% versus -820.2% for ARMP. At the gross margin level — before operating expenses — LLY leads at 81.3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Is ARMP or LLY more undervalued right now?
Analyst consensus price targets imply the most upside for LLY: 21.0% to $1214.28.
06Which pays a better dividend — ARMP or LLY?
In this comparison, LLY (0.5% yield) pays a dividend. ARMP does not pay a meaningful dividend and should not be held primarily for income.
07Is ARMP or LLY better for a retirement portfolio?
For long-horizon retirement investors, Eli Lilly and Company (LLY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.65), 0.5% yield, +1316% 10Y return). Both have compounded well over 10 years (LLY: +1316%, ARMP: -98.0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between ARMP and LLY?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. LLY pays a dividend while ARMP does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.